Pharmacogenomics and adverse drug reactions

被引：7

作者：

Amur, Shashi ^{[1
]}

Zineh, Issam ^{[1
]}

Abernethy, Darrell R. ^{[1
]}

Huang, Shiew-Mei ^{[1
]}

Lesko, Lawrence J. ^{[1
]}

机构：

[1] Ctr Drug Evaluat & Res, Off Translat Sci, Off Clin Pharmacol, PDA, Silver Spring, MD 20998 USA

来源：

PERSONALIZED MEDICINE | 2010年 / 7卷 / 06期

关键词：

adverse drug reaction; CYP; drug label; drug-metabolizing enzymes; drug safety; genetic; genomic; polymorphism; variant; ABACAVIR HYPERSENSITIVITY; CLINICAL-PRACTICE; RATES; TOXICITY; INDUSTRY; HLA-B-ASTERISK-5701; POLYMORPHISMS; TRANSPORTERS; INTEGRATION; BIOMARKERS;

D O I：

10.2217/PME.10.63

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Adverse drug reactions (ADRs) observed during drug development have been the cause for discontinuing development of many drugs. In addition, serious but rare ADRs observed after marketing have led to withdrawal of some drugs. A priori identification of individuals at risk of developing ADRs for a given drug will help develop strategies to reduce the risk for ADRs in these patients. US FDA initiatives and efforts at reducing ADRs to make drugs safer are described, including updating of drug labels to include genomic information intended to reduce ADRs. Pharmacogenomics can also be harnessed to identify individuals at risk of developing serious ADRs and to treat these individuals with alternative therapy, thus converting ADRs that are traditionally considered unavoidable to avoidable ADRs.

引用

页码：633 / 642

页数：10

共 50 条

[1] Pharmacogenomics of adverse drug reactions
Daly, Ann K.
[J]. GENOME MEDICINE, 2013, 5
[2] Pharmacogenomics of adverse drug reactions
Ann K Daly
[J]. Genome Medicine, 5
[3] Pharmacogenomics and adverse drug reactions
Chiba, K
[J]. JAPANESE JOURNAL OF PHARMACOLOGY, 2002, 88 : 46P - 46P
[4] The role of pharmacogenomics in adverse drug reactions
Cacabelos, Ramon
Cacabelos, Natalia
Carril, Juan C.
[J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (05) : 407 - 442
[5] Advances in the Pharmacogenomics of Adverse Drug Reactions
Susannah L. Collins
Daniel F. Carr
Munir Pirmohamed
[J]. Drug Safety, 2016, 39 : 15 - 27
[6] Pharmacogenomics and adverse drug reactions in children
Rieder, Michael J.
Carleton, Bruce
[J]. FRONTIERS IN GENETICS, 2014, 5
[7] Advances in the Pharmacogenomics of Adverse Drug Reactions
Collins, Susannah L.
Carr, Daniel F.
Pirmohamed, Munir
[J]. DRUG SAFETY, 2016, 39 (01) : 15 - 27
[8] Editorial: Pharmacogenomics of Adverse Drug Reactions
Siddiqui, Moneeza K.
Luzum, Jasmine
Coenen, Marieke
Mahmoudpour, Seyed Hamidreza
[J]. FRONTIERS IN GENETICS, 2022, 13
[9] Advances in the pharmacogenomics of adverse drug reactions
I Alvarado
M-L Wong
J Licinio
[J]. The Pharmacogenomics Journal, 2002, 2 (5) : 273 - 273
[10] Adverse drug reactions: role of pharmacogenomics
Severino, G
Del Zompo, M
[J]. PHARMACOLOGICAL RESEARCH, 2004, 49 (04) : 363 - 373

← 1 2 3 4 5 →